Pharma Two B was founded by a group of highly experienced professionals from the Israeli pharmaceutical industry, with strong track record in drug delivery, chemistry, finance and strategic planning. The company's management and staff are highly skilled scientists with many years of experience in research and development of drugs, pharmaceutical development and clinical trials.
Dr. Nurit Livnah - CEO
Dr. Livnah received her Ph.D in Chemistry from the Weizmann Institute of Science. She brings over 18 years of experience in drug discovery and development, project management and team leadership. Among her former positions, she spent 8 years at Peptor Ltd, where she led projects in anti-cancer drug development, first as the Head of Chemistry group and later as VP R&D. She then served as Director of research of DeveloGen Israel, and then as VP R&D at Proteologics Ltd, where she was involved in drug discovery and development of anti-cancer and anti-viral agents. She joined Pharma Two B upon the establishment of the company in January 2008.
Irit Zalayet - CFO
Ms. Irit Zalayet CPA serves as Pharma Two B’s CFO as of September 2010. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar-Ilan University. Ms. Zalayet also serves as the CFO of a related group party Stem Cell Medicine.
Hadas Friedman - VP QA, RA and Clinical Affairs
Mrs. Hadas Friedman serves as Pharma Two B's VP QA, RA and Clinical Affairs. Prior to this Hadas has served as VP QA, RA and Clinical Affairs at Intec Pharma Ltd., a drug development company, for over 8 years, and as head of QA at Procognia Ltd., a biotech company specializing in micro-array technologies, for over 4 years. Prior to that, she served as an associate in the quality department in Rafa Laboratories, Jerusalem, a pharmaceutical company. While at Intec Pharma, Hadas has conducted and managed over 20 clinical trials in several indications, including Parkinson's disease, in healthy volunteers and patients. Hadas holds an MSc in molecular biology and BSc in Life Sciences from Bar-Ilan University in Israel.
Board of Directors
Ehud Marom - Chairman of the Board
Mr. Marom received his B.Sc. in Chemical Engineering from the Technion – Israel Institute of Technology with distinction. He brings vast experience in management, operations, business and strategic planning in the pharmaceutical industry, where he has held various senior positions over the years, among them, V.P. of Operations at Teva Pharmaceuticals API and Innovative divisions, where he was credited for his contribution to the market success of Teva; COO of Peptor Ltd; CEO of the Jerusalem based biotechnology company, Gamida-cell, a leader in hematopoietic (blood) stem cell therapeutics; President and CEO of Makhteshim Chemical Works Ltd., followed by position of senior VP for supply chain in Makhteshim-Agan Group. Currently Mr. Marom acts as the Chairman & CEO of the Mapi Pharma as well as Chairman & CEO of Stem Cell Medicine Ltd.
Ms. Bertolini currently operates as a Project Analyst in Generali Groups Private Equity Department where she is engaged in evaluation and investments in different maturity stages. Ms. Bertolini has hands-on experience in development of deals and later follows the development of key investments actively as board member. Ms. Bertolini’s experience in the Generali Group includes underwriting of foreign contract insurance and bond analysis. Prior to Generali she worked at Banca Nazionale del Lavoro SpA (BNL) specializing in trade financing and international transactions. Ms. Bertolini received her MA in International Trade and her BA in Business Administration.
Mr. Kronfeld founded JK&B in 1996. Mr. Kronfeld is an experienced venture capital investor with over 30 years of experience. Prior to forming JK&B, Mr. Kronfeld was a General Partner at Boston Capital Ventures ("BCV") where he focused on making venture capital investments. Before joining BCV, Mr. Kronfeld was with Ameritech where he was the Vice President of Acquisitions and Venture Investments responsible for directing Ameritech's venture capital investments and all of Ameritech's mergers and acquisitions activities. In addition, Mr. Kronfeld was a Senior Manager at Booz Allen & Hamilton and a Systems Analyst at Electronic Data Systems (E.D.S.). Mr. Kronfeld earned a Bachelor of Science in Electrical Engineering with high honors and a Master of Science in Computer Science from Stevens Institute of Technology and a Master of Business Administration from The Wharton School of Business.
Dr. Itamar Borowitz
Itamar Borowitz, PhD served as the chief executive officer of Israel’s third largest insurance company, Phoenix Insurance Company Ltd., from 1992 to 2001, following a 27 year career within the Phoenix Insurance Group, during which he held a variety of senior management positions. Since 2009, Dr. Borowitz has served as the chief executive officer of BIT Enterprises Ltd., an advisor to Generali Financial Holdings, a European capital fund. From 2005 to 2008, Dr. Borowitz served as a strategic advisor to the Post of Israel, and since 2001, as a member of the advisory board and a representative to Israel of GLL Real Estate Partners GmBH. Previously, Dr. Borowitz served as the chief executive officer of Dolev Insurance Co. Ltd., as the chairman of the board of directors of Surdam, Lloyd’s agent in Israel, as the chairman of Israel Insurance Association, the chairman of Academic College of Insurance and a director of Mehadrin Ltd., the largest citrus company in Israel. Dr. Borowitz serves as the Chairman of the Board of Inbal Pinto and Avshalom Polak Dance Company. Dr. Borowitz hold a PhD in High Energy Physics, an MBA and B.A. in General History from Tel Aviv University, Israel, and a B.Sc. in Mathematics and Physics from the Hebrew University of Jerusalem, Israel.
Dr. David Leonov
Dr. David Leonov gained extensive experience in chemistry, API and development of generic products; formerly at Teva, holding senior research positions, and later at Makhteshim-Agan, where he served as the group’s Chief Scientist.
Mr. Mittelman, a long standing industrialist focused on the food industry and a private investor in Pharmaceutical formulation companies (Lead investor in Karma Pharm - Exit to Lycored 2004). Mr. Mittelman received his B.Sc. in Chemical Engineering and Food Technology from the Technion – Israel Institute of Technology and is currently the co-owner and CEO of Starkist Fodor an importer and manufacturer of canned fish products. Mr. Mittelman and his family, immigrated to Israel from Uruguay, have been engaged in shaping the growing Israeli food industry for years and have been owners and manufacturers of top household food brands such as Yitzhar Oils. Mr. Mittelman’s deep understandings of industry, chemistry, regulation and innovation have led him to successful investments in the pharmaceutical industry.